Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 12/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23842302 | 1.00 | DDB1 (0.49) | DDB1CRBNADORA3TRIM24STAT3 | |
| SCHEMBL22776794 | 1.00 | DDB1 (0.49) | DDB1CRBNADORA3TRIM24STAT3 | |
| SCHEMBL29991318 | 1.00 | DDB1 (0.49) | DDB1CRBNADORA3TRIM24STAT3 | |
| SCHEMBL25123857 | 1.00 | DDB1 (0.49) | DDB1CRBNADORA3TRIM24STAT3 | |
| SCHEMBL30392222 | 1.00 | DDB1 (0.49) | DDB1CRBNADORA3TRIM24STAT3 | |
| SCHEMBL25123418 | 0.99 | DDB1 (0.49) | DDB1CRBNADORA3TRIM24STAT3 | |
| SCHEMBL29991684 | 0.99 | DDB1 (0.49) | DDB1CRBNADORA3TRIM24STAT3 | |
| SCHEMBL21996743 | 0.97 | DDB1 (0.50) | DDB1CRBNTRIM24STAT3DRD2 | |
| SCHEMBL23832591 | 0.94 | DDB1 (0.51) | DDB1CRBNTRIM24STAT3 | |
| SCHEMBL21070373 | 0.93 | DDB1 (0.49) | DDB1CRBNTRIM24STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | DDB1 206/4885CRBN 302/4885ADORA3 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.